CRISPR THERAPEUTICS AG Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
CRISPR THERAPEUTICS AG (CRSP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-02-12
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2019-03-31 was 2.50%, a 7.41% decline year-over-year.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2018-03-31 was 2.70%.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.00%, a 4.76% decline from fiscal 2024.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.20%, a 2.44% increase from fiscal 2023.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.10%, a 57.69% increase from fiscal 2022.
- CRISPR THERAPEUTICS AG share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.60%, a 160.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.00% 10-K · filed 2026-02-12 | |||
| 2024-12-31 | 4.20% 10-K · filed 2026-02-12 | |||
| 2023-12-31 | 4.10% 10-K · filed 2026-02-12 | |||
| 2022-12-31 | 2.60% 10-K · filed 2025-02-11 | |||
| 2021-12-31 | 1.00% 10-K · filed 2024-02-21 | |||
| 2020-12-31 | 0.60% 10-K · filed 2023-02-21 | |||
| 2019-12-31 | 2.20% 10-K · filed 2022-02-15 | |||
| 2019-09-30 | 2.40% 10-Q · filed 2019-10-28 | |||
| 2019-06-30 | 2.50% 10-Q · filed 2019-07-29 | |||
| 2019-03-31 | 2.50% 10-Q · filed 2019-04-29 | |||
| 2018-12-31 | 2.80% 10-K · filed 2021-02-16 | |||
| 2018-09-30 | 2.70% 10-Q · filed 2019-10-28 | |||
| 2018-06-30 | 2.70% 10-Q · filed 2019-07-29 | |||
| 2018-03-31 | 2.70% 10-Q · filed 2019-04-29 | |||
| 2017-12-31 | 2.00% 10-K · filed 2020-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |